Related Experiment Video

Updated: Jul 14, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure

Jianing Wang1, Jiannan Feng, Ming Shi

  • 1Institute of Basic Medical Sciences, Taiping Road 27, Beijing 100850, PR China.

Molecular Immunology
|June 19, 2007
PubMed

Insights

Researchers developed a novel peptide targeting ErbB2-overexpressing tumors. This chimeric molecule, PL45, demonstrated stability and effectively inhibited tumor cell growth, offering potential for cancer immunotherapy.

Area of Science:

  • Oncology
  • Biochemistry
  • Immunology

Background:

  • Extracellular cysteine-rich domains of ErbB2 receptors are crucial for ligand binding and receptor dimerization.
  • ErbB2 overexpression is implicated in various cancers, making it a significant therapeutic target.

Purpose of the Study:

  • To design a novel peptide with cytostatic effects on ErbB2-overexpressing tumors.
  • To create a stable chimeric molecule, PL45, by combining an ErbB2 S1 domain targeting peptide with a cartilage oligomeric matrix protein (COMP) coiled coil domain.

Main Methods:

  • Generation of a chimeric molecule (PL45) by fusing ErbB2 S1 domain peptide with COMP coiled coil domain.
  • Expression of PL45 in Escherichia coli.
  • Assessment of PL45's thermal and pH stability.
  • Evaluation of PL45's ability to interfere with ErbB2 dimerization and inhibit tumor cell growth in vitro and in vivo.

Main Results:

  • PL45 was efficiently expressed and exhibited high thermal and pH stability.
  • PL45 demonstrated the capability to interfere with ErbB2 receptor dimerization.
  • PL45 effectively inhibited the growth of ErbB2-overexpressing tumor cells in both in vitro and in vivo models.

Conclusions:

  • The coiled coil structure serves as a viable scaffold for stabilizing short peptides for therapeutic applications.
  • The S1 domain of ErbB2 is a promising target for the development of novel anti-cancer drugs.
  • PL45 shows potential for anti-cancer immunotherapy against ErbB2-overexpressing tumors.

More Related Videos

Production, Crystallization, and Structure Determination of the IKK-binding Domain of NEMO13:02

Production, Crystallization, and Structure Determination of the IKK-binding Domain of NEMO

Published on: December 28, 2019

Related Concept Videos

Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Tail-anchoring of Proteins in the ER Membrane01:45

Tail-anchoring of Proteins in the ER Membrane

Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
ER Retrieval Pathway01:45

ER Retrieval Pathway

In the secretory pathway, vesicles transport proteins from one cellular compartment to another in forward transport to deliver the protein to its correct location. Occasionally, misfolded proteins and incorrect proteins escape their original compartments, and a retrieval pathway is used to return the escaped proteins to their original compartment.
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
GPI Anchoring of Proteins in the ER Membrane01:29

GPI Anchoring of Proteins in the ER Membrane

GPI-anchoring is a post-translational, reversible protein modification that is ubiquitous in eukaryotes. Such proteins are primarily present on the exoplasmic leaflet of the plasma membrane.
GPI-anchor structure
A sequence of 11 enzymatic reactions results in the synthesis of the complete GPI anchor consisting of a hydrophobic and a hydrophilic portion. The hydrophobic portion comprises phosphatidylinositol, while the hydrophilic part comprises polar groups like phosphoethanolamine,...